Our study has proven that ACSS2 acts as a tumorigenic factor in melanoma, aggregating tumor growth and metastasis while inhibiting stress-triggered apoptosis, positioning ACSS2 as a viable therapeutic target for melanoma treatment. The gene discussed is ACSS2; the disease is neoplasm.